CURE Pharmaceutical to Participate in Panel Discussion on the Future of Clinical Research using Cannabis at The Cannabis Science Conference in Portland, OR
August 29, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., Aug. 29, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis
August 22, 2017 11:19 ET
|
CURE Pharmaceutical
OXNARD, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, today announced that its subsidiary company, Oak...
CURE Pharmaceutical Enters Partnership to Distribute New Erectile Dysfuntion Drug Using Company’s Proprietary CureFilm™ Into Asian Market
August 10, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids
July 11, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif. and TEL AVIV, Israel, July 11, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid...
CURE Pharmaceutical Expects Increased Demand for Its Enhanced Transdermal Drug Delivery Platform
July 05, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical Appoints CannaKids CEO and Cannabis Cancer Advocate Tracy Ryan to Advisory Board
June 27, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., June 27, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market
June 07, 2017 11:13 ET
|
CURE Pharmaceutical
OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical and CannaKids Announce Research Collaboration with Technion-Israel Institute of Technology on Cancer-Fighting Cannabinoids
May 31, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.
May 24, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...
CURE Pharmaceutical Announces Crosslink Patent for Covering Company’s Proprietary CureFilm™ Drug Delivery Technology
May 18, 2017 09:00 ET
|
CURE Pharmaceutical
OXNARD, Calif., May 18, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development...